[Biofilm: set-up and organization of a bacterial community].
Bacterial attachment on various surfaces mostly takes place in the form of specialised bacterial communities, referred to as biofilm. The biofilm is formed through series of interactions between cells and adherence to surface, resulting in an organised structure. In this review we have been using Pseudomonas aeruginosa as a model microorganism to describe the series of events that occurred during this developmental process. P. aeruginosa is an opportunistic pathogen that has a wide variety of hosts and infectious sites. In addition to biofilm formation in certain tissues, inert surfaces, such as catheters, are also target for bacterial biofilm development. The use of convenient genetic screens has made possible the identification of numerous biofilm-defective mutants, which have been characterised further. These studies have allowed the proposal for a global model, in which key events are described for the different stages of biofilm formation. Briefly, flagellar mobility is crucial for approaching the surface, whereas type IV pili motility is preponderant for surface colonisation and microcolonies formation. These microcolonies are finally packed together and buried in an exopolysaccharide matrix to form the differentiated bio-film. It is obvious that the different stages of biofilm formation also involved perception of environmental stimuli. These stimuli, and their associated complex regulatory networks, have still to be fully characterised to understand the bacterial strategy, which initiates biofilm formation. One such regulatory system, called Quorum sensing, is one of the key player in the initial differentiation of biofilm. Finally, a better understanding, at the molecular level, of biofilm establishment and persistence should help for the design of antimicrobials that prevent bacterial infections.
Filloux
Alain
A
Laboratoire d'Ingénierie des Systèmes Macromoléculaires, UPR 9027, IBSM/Cnrs, 31, Chemin Joseph Aiguier, 13402 Marseille, France.
Vallet
Isabelle
I
D000464:Alginates / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001422:Bacterial Adhesion; D018441:Biofilms / Q000254:growth & development; D002404:Catheterization / Q000009:adverse effects; D015195:Drug Design; D004866:Equipment Contamination; D010861:Fimbriae, Bacterial / Q000502:physiology; D015964:Gene Expression Regulation, Bacterial; D005798:Genes, Bacterial; D020723:Glucuronic Acid; D006603:Hexuronic Acids; D006801:Humans; D008070:Lipopolysaccharides / Q000378:metabolism; D008954:Models, Biological; D016459:Prosthesis-Related Infections / Q000382:microbiology; D011552:Pseudomonas Infections / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity / Q000502:physiology; D013045:Species Specificity
D000464:Alginates; D000900:Anti-Bacterial Agents; D006603:Hexuronic Acids; D008070:Lipopolysaccharides; D020723:Glucuronic Acid